XML 32 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Net Loss per Share (Tables)
 6 Months Ended
Jun. 30, 2024
Earnings Per Share [Abstract]  
Schedule of computation of basic and diluted net loss per share

The following table sets forth the computation of basic and diluted net loss per share for the three months ended June 30, 2024 and 2023 (in thousands, except share and per share amounts):

 

 

Three Months Ended June 30,

 

 

For the Six Months Ended June 30,

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Numerator

 

 

 

 

 

 

 

 

 

 

 

Net loss

$

(38,466

)

 

$

(34,823

)

 

$

(73,799

)

 

$

(71,732

)

Less: Net loss attributable to noncontrolling interests

 

(25,960

)

 

 

(25,705

)

 

 

(51,801

)

 

 

(52,949

)

Net loss available to Class A ordinary shareholders of ProKidney Corp.,
   basic and diluted

$

(12,506

)

 

$

(9,118

)

 

$

(21,998

)

 

$

(18,783

)

 

 

 

 

 

 

 

 

 

 

 

 

Denominator

 

 

 

 

 

 

 

 

 

 

 

Weighted average Class A ordinary shares or ProKidney Corp. outstanding,
   basic and diluted

 

75,908,017

 

 

 

64,562,209

 

 

 

68,429,869

 

 

 

64,551,281

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per Class A ordinary share

 

 

 

 

 

 

 

 

 

 

 

Net loss per Class A ordinary share of ProKidney Corp., basic and diluted

$

(0.16

)

 

$

(0.14

)

 

$

(0.32

)

 

$

(0.29

)

 

Outstanding anti-dilutive securities not included in the diluted net loss per share calculation include the following:

 

 

As of June 30,

 

 

2024

 

 

2023

 

Antidilutive securities

 

 

 

 

 

ProKidney Corp. Class B ordinary shares

 

163,817,953

 

 

 

173,663,427

 

Unvested Restricted Stock Rights

 

2,188,728

 

 

 

5,952,288

 

Earnout Rights

 

17,500,000

 

 

 

17,500,000

 

Stock options granted under the 2022 Equity Incentive Plan

 

21,916,121

 

 

 

15,718,932